Comparison of Safety and Efficacy of TOCOSOL(R) Paclitaxel Versus Taxol(R) for Treatment of Metastatic Breast Cancer
Public ClinicalTrials.gov record NCT00251095. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter Phase 3, Randomized Comparison of the Safety and Efficacy of Weekly TOCOSOL(R) Paclitaxel vs. Weekly Paclitaxel Injection in the Treatment of Metastatic Breast Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to compare the objective response rates of patients randomized to receive either TOCOSOL(R) Paclitaxel or Taxol(R) (paclitaxel injection) administered every week to patients with metastatic breast cancer. The study hypothesis is that the objective response rate with TOCOSOL Paclitaxel given every week is non-inferior to that observed with Taxol given every week.
Study identification
- NCT ID
- NCT00251095
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 821 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2005
- Primary completion
- Aug 31, 2007
- Completion
- Aug 31, 2007
- Last update posted
- Jun 3, 2009
2005 – 2007
United States locations
- U.S. sites
- 14
- U.S. states
- 10
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alta Bates Comprehensive Cancer Center | Berkeley | California | 94704 | — |
| Desert Hematology Oncology Medical Group | Rancho Mirage | California | 92270 | — |
| Stockton Hematology Oncology | Stockton | California | 95204 | — |
| Florida Cancer Specialists | Fort Myers | Florida | 33901 | — |
| Mountain State Tumor Institute | Boise | Idaho | 83712 | — |
| Oncology Care Associates | Saint Joseph | Michigan | 49085 | — |
| Southfield Oncology Institute, Inc | Southfield | Michigan | 48076 | — |
| Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center | Lebanon | New Hampshire | 03756 | — |
| Essex Oncology of North Jersey | Belleville | New Jersey | 07109 | — |
| Mid Dakota Clinic | Bismarck | North Dakota | 58501 | — |
| Hematology Oncology Consultants, Inc | Columbus | Ohio | 43235 | — |
| Chattanooga Oncology & Hematology Associates, PC | Chattanooga | Tennessee | 37404 | — |
| The Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| Joe Arrington Cancer Research and Treatment Center | Lubbock | Texas | 79410 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00251095, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 3, 2009 · Synced Sep 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00251095 live on ClinicalTrials.gov.